CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 71 enrolled
Drug / intervention
B244 suspension +1 morebiological
Likely dose
B244 suspension 30mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03290248
NCT03290248Phase 2Completed
CompareCT.gov

A Prospective, Controlled, Double Blind, Multi-Center, Randomized, 3 Arm, Phase 1b/2a Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 Delivered as an Intranasal Spray in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

AOBiome LLC·interventional·Posted Sep 21, 2017·Updated Nov 25, 2022

In Brief

A Phase 2 clinical trial evaluating B244 suspension and Vehicle for Allergic Rhinitis and 2 related conditions. Completed, enrolled 71 participants across 2 sites in 2 countries.

Detailed Summary

This is a Prospective, Controlled, Double Blinded, Single Center, Randomized, 3 Arm, Parallel Assignment, Phase 1b/2a Study to assess the safety, tolerability, and preliminary efficacy of B244 delivered as an intranasal spray in healthy volunteers and subjects with seasonal allergic rhinitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis, Allergic Rhinitis Due to Grass Pollen, Healthy Volunteers
CountriesCanada, United States
CollaboratorsOrange County Research Center, Integrium

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 21, 2017
Enrollment StartSep 19, 2017
Primary CompletionDec 21, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.8 years ago

Interventions

B244 suspensionbiological

B244 suspension in 30ml/bottle

Vehiclebiological

Vehicle, 30ml/bottle